Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Recruiting

Phase 2

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Sponsor:

Memorial Sloan Kettering Cancer Center

Code:

NCT04469075

Conditions

Glioblastoma

Recurrent Glioblastoma

Skin Toxicity

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Clindamycin Phosphate

Triamcinolone Acetonide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center on 2024-11-08.